CACLP - The largest IVD Expo & Conference

FDA Approves Foundation Medicine CDx Tests for Pfizer's Braftovi-Mektovi Combo in Lung Cancer

Industry news | 13 October, 2023 | CACLP

Original from: 360dx

 

Roche subsidiary Foundation Medicine announced on Thursday that the US Food and Drug Administration has approved two of its companion diagnostic tests for use with Pfizer's Braftovi (encorafenib) in combination with Mektovi (binimetinib) for patients with metastatic non-small cell lung cancer with a BRAF V600E mutation.

 

The FoundationOne CDx and FoundationOne Liquid CDx assays were approved to determine if NSCLC patients are eligible for treatment with the drug combination, which was also approved by the FDA this week. The kinase inhibitors were previously approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. 

 

The next-generation sequencing-based tests analyze more than 300 genes and are approved for multiple cancer indications. FoundationOne CDx uses DNA isolated from formalin-fixed, paraffin-embedded tumor tissue specimens, while FoundationOne Liquid CDx utilizes circulating cell-free DNA from a blood sample. 

 

"We are thrilled to see both tests approved simultaneously for the same indication, which will expand access to this therapy option to more NSCLC patients who harbor a BRAF V600E mutation," Foundation Medicine Chief Medical Officer Mia Levy said in a statement. 

Source: FDA Approves Foundation Medicine CDx Tests for Pfizer's Braftovi-Mektovi Combo in Lung Cancer

 

Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference